• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Ocular Therapeutix Inc.

    11/14/24 7:30:26 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OCUL alert in real time by email
    S-8 1 tm2428320d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on November 14, 2024

     

    Registration No. 333-_____

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    OCULAR THERAPEUTIX, INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

    Delaware 20-5560161
    (State or Other Jurisdiction of Incorporation
    or Organization)
    (I.R.S. Employer
    Identification No.)
       

    15 Crosby Drive

    Bedford, MA

    01730
    (Address of Principal Executive Offices) (Zip Code)

     

    2019 Inducement Stock Incentive Plan

    (Full Title of the Plan)

     

    Pravin U. Dugel, M.D.

    Executive Chairman, President and Chief Executive Officer

    Ocular Therapeutix, Inc.

    15 Crosby Drive

    Bedford, MA 01730
    (Name and Address of Agent for Service)

     

    (781) 357-4000

    (Telephone Number, Including Area Code, of Agent for Service)

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨ Accelerated filer ¨
    Non-accelerated filer x Smaller reporting company x
        Emerging Growth Company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8, relating to 1,250,000 shares of the common stock, $0.0001 par value per share (the “Common Stock”), issuable under the 2019 Inducement Stock Incentive Plan, as amended (the “2019 Inducement Plan”), of Ocular Therapeutix, Inc. (the “Registrant”) is being filed with the Securities and Exchange Commission (the “SEC”) for the purpose of registering additional securities of the same class as other securities for which a Registration Statement on Form S-8 has previously been filed and is effective. Accordingly, this Registration Statement incorporates by reference the contents of (i) the Registration Statement on Form S-8 (File No. 333-237115) filed with the SEC on March 12, 2020, by the Registrant relating to the Registrant’s 2014 Stock Incentive Plan (the “2014 Plan”), the Registrant’s 2014 Employee Stock Purchase Plan (the “2014 ESPP”), and the 2019 Inducement Plan; (ii) the Registration Statement on Form S-8 (File No. 333-254143) filed with the SEC on March 11, 2021, by the Registrant relating to the 2014 Plan, the 2014 ESPP and the 2019 Inducement Plan; (iii) the Registration Statement on Form S-8 (File No. 333-277244) filed with the SEC on February 22, 2024, by the Registrant relating to the 2019 Inducement Plan; and (iv) the Registration Statement on Form S-8 (File No. 333-279176) filed with the SEC on May 7, 2024, by the Registrant relating to the 2019 Inducement Plan, in each case, except to the extent amended or superseded by the contents hereof and, in the case of items (i) and (ii) above, as amended by Post-Effective Amendment No. 1 to Form S-8 Registration Statements relating to such Form S-8 Registration Statement, filed with the SEC on August 9, 2021.

     

     

    Item 8. Exhibits.

     

    The following exhibits are incorporated herein by reference.

     

    Number Description
       
    4.1(1) Restated Certificate of Incorporation of the Registrant, as amended
       
    4.2(2) Amended and Restated By-laws of the Registrant
       
    4.3(3) Registration Rights Agreement, dated as of March 1, 2019, by and among the Registrant and the Purchasers identified therein
       
    4.4(4) Registration Rights Agreement, dated as of February 21, 2024, by and among the Registrant and the other parties thereto
       
    5.1 Opinion of Wilmer Cutler Pickering Hale and Dorr LLP
       
    23.1 Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1)
       
    23.2 Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm
       
    24.1 Power of Attorney (included on signature page)
       
    99.1(5) 2019 Inducement Stock Incentive Plan
       
    99.2(6) Amendment to 2019 Inducement Stock Incentive Plan
       
    99.3(7) Amendment No. 2 to 2019 Inducement Stock Incentive Plan
       
    99.4(8) Amendment No. 3 to 2019 Inducement Stock Incentive Plan
       
    99.5(9) Amendment No. 4 to 2019 Inducement Stock Incentive Plan
       
    107 Filing Fee Table

     

    (1)Previously filed with the Securities and Exchange Commission on August 7, 2024, as Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-36554) and incorporated herein by reference.

     

    (2)Previously filed with the Securities and Exchange Commission on July 30, 2014, as Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-36554) and incorporated herein by reference.

     

    (3)Previously filed with the Securities and Exchange Commission on March 7, 2019, as Exhibit 4.2 to the Registrant’s Annual Report on Form 10-K (File No. 001-36554) and incorporated herein by reference.

     

    (4)Previously filed with the Securities and Exchange Commission on February 22, 2024, as Exhibit 10.2 to the Registrant’s Current Report on Form 8-K (File No. 001-36554) and incorporated herein by reference.

     

    (5)Previously filed with the Securities and Exchange Commission on November 12, 2019, as Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-36554) and incorporated herein by reference.

     

    (6)Previously filed with the Securities and Exchange Commission on March 11, 2021, as Exhibit 10.9 to the Registrant’s Annual Report on Form 10-K (File No. 001-36554) and incorporated herein by reference.

     

    (7)Previously filed with the Securities and Exchange Commission on February 22, 2024, as Exhibit 10.5 to the Registrant’s Current Report on Form 8-K (File No. 001-36554) and incorporated herein by reference.

     

    (8)Previously filed with the Securities and Exchange Commission on April 18, 2024, as Exhibit 99.1 to the Registrant’s Current Report on Form 8-K (File No. 001-36554) and incorporated herein by reference.

     

    (9)Previously filed with the Securities and Exchange Commission on October 9, 2024, as Exhibit 99.1 to the Registrant’s Current Report on Form 8-K (File No. 001-36554) and incorporated herein by reference.

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Bedford, Massachusetts, on this 14th day of November, 2024.

     

    OCULAR THERAPEUTIX, INC.  
       
    By: /s/ Pravin U. Dugel, M.D.  
      Pravin U. Dugel, M.D.  
      Executive Chairman, President and Chief Executive Officer  

     

    POWER OF ATTORNEY AND SIGNATURES

     

    We, the undersigned officers and directors of Ocular Therapeutix, Inc., hereby severally constitute and appoint Pravin Dugel, M.D. and Donald Notman, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Ocular Therapeutix, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

     

     

    Signature   Title   Date
             
    /s/ Pravin U. Dugel, M.D.   Executive Chairman of the Board of Directors, President and Chief Executive Officer (Principal Executive Officer)   November 14, 2024
    Pravin U. Dugel, M.D.      
           
    /s/ Donald Notman   Chief Operating Officer and Chief Financial Officer (Principal Financial and Accounting Officer)   November 14, 2024
    Donald Notman      
             
    /s/ Adrienne Graves, Ph.D.   Director   November 14, 2024
    Adrienne Graves, Ph.D.        
             
    /s/ Seung Suh Hong, Ph.D.   Director   November 14, 2024
    Seung Suh Hong, Ph.D.        
             
    /s/ Richard L. Lindstrom, M.D.   Director   November 14, 2024
    Richard L. Lindstrom, M.D.        
             
    /s/ Merilee Raines   Director   November 14, 2024
    Merilee Raines        
             
    /s/ Charles Warden   Director   November 14, 2024
    Charles Warden        
             
    /s/ Leslie Williams   Director   November 14, 2024
    Leslie Williams        

     

     

     

    Get the next $OCUL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OCUL

    DatePrice TargetRatingAnalyst
    4/8/2025Outperform
    William Blair
    3/18/2025$17.00Outperform
    RBC Capital Mkts
    3/11/2025$15.00Buy
    Needham
    10/16/2024Sector Outperform
    Scotiabank
    6/20/2024$7.00 → $11.00Hold → Buy
    TD Cowen
    5/31/2024$15.00Overweight
    Piper Sandler
    2/9/2024$15.00Buy
    BofA Securities
    4/21/2023$18.00Outperform
    Robert W. Baird
    More analyst ratings

    $OCUL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lindstrom Richard L Md bought $69,600 worth of shares (10,000 units at $6.96), increasing direct ownership by 6% to 172,704 units (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      5/12/25 8:50:46 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Dugel Pravin sold $147,533 worth of shares (21,475 units at $6.87), decreasing direct ownership by 0.61% to 3,520,318 units (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      2/26/25 6:27:13 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Heier Jeffrey S. sold $21,029 worth of shares (3,061 units at $6.87), decreasing direct ownership by 1% to 265,998 units (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      2/26/25 6:25:32 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUL
    SEC Filings

    See more
    • SEC Form 10-Q filed by Ocular Therapeutix Inc.

      10-Q - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

      5/5/25 7:47:55 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

      5/5/25 7:06:05 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Ocular Therapeutix Inc.

      DEFA14A - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

      4/29/25 5:01:27 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ocular Therapeutix™ to Participate in Upcoming Investor Conferences

      BEDFORD, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor conferences in the second half of May 2025. 2025 RBC Capital Markets Global Healthcare Conference, May 20, 2025 Fireside Chat Date: Tuesday, May 20, 2025Fireside Chat Time: 2:35PM ETPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: New York, NY HC Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ, May 20, 2025Fireside Chat Date: Tuesday, May 20, 2025Fireside Chat Time: 4:30PM ETPresenter: Pravin

      5/14/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights

      AXPAXLI™ SOL trials for wet AMD progressing rapidly following recent updates to accelerate and enhance the registrational program Following positive FDA feedback for potential AXPAXLI NPDR registrational trial, Ocular is actively planning next steps in NPDR and DME SOL-1 retention remains exceptional as trial is on track for 1Q 2026 topline data readout SOL-R continues to have strong enrollment through streamlined, accelerated execution Cash balance of $349.7M as of March 31, 2025, with expected runway through topline data for SOL-1 and SOL-R and into 2028 BEDFORD, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a fully-integrated biopharma

      5/5/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ to Participate in Upcoming Investor and Scientific Conferences

      BEDFORD, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in the first half of May 2025. Upcoming Investor Conferences Citizens JMP Life Sciences Conference 2025:Fireside Chat Date: Wednesday, May 7, 2025Fireside Chat Time: 9:00 AM ETPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: New York, NY Bank of America 2025 Global Healthcare Conference:Fireside Chat Date: Tuesday, May 13, 2025Fireside Chat Time: 9:20 AM PTPresenter: Pravin U. Dugel, MD, Executive C

      4/29/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

      SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

      11/14/24 5:49:38 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ocular Therapeutix Inc.

      SC 13G - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

      11/14/24 9:37:26 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

      SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

      11/12/24 4:49:23 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Ocular Therapeutix

      William Blair initiated coverage of Ocular Therapeutix with a rating of Outperform

      4/8/25 9:29:59 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on Ocular Therapeutix with a new price target

      RBC Capital Mkts initiated coverage of Ocular Therapeutix with a rating of Outperform and set a new price target of $17.00

      3/18/25 7:53:57 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham initiated coverage on Ocular Therapeutix with a new price target

      Needham initiated coverage of Ocular Therapeutix with a rating of Buy and set a new price target of $15.00

      3/11/25 7:42:03 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUL
    Financials

    Live finance-specific insights

    See more
    • Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025

      BEDFORD, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to issue a press release regarding first quarter 2025 financial results on Monday, May 5, 2025 at 7:00 AM Eastern Time. The Company will not be hosting a first quarter 2025 conference call and plans to resume quarterly earnings calls for its second quarter 2025 financial results. Information about the Company's quarterly results, conference calls, webcasts and other investor information are posted on the Company's website. About Ocular Therapeutix, Inc.Ocular Therapeutix, Inc.

      4/28/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2024 Results and Business Highlights

      Announces several updates to enhance and accelerate AXPAXLI registrational program in wet AMD, potentially supporting label flexibility of 6-12 months to showcase expected best-in-class durability FDA approves Amendment to SOL-1 Special Protocol Agreement (SPA) to include AXPAXLI re-dosing at Weeks 52 and 76 SOL-1 trial Week 36 primary endpoint data now expected in 1Q 2026 due to requirement for masking until Week 52 to allow for re-dosing Inclusion of re-dosing in SOL-1, along with exceptional retention seen to date in the study, paves way for reduction of SOL-R trial size to 555 subjects (previously 825), potentially accelerating registration timelines Additional updates provided on SO

      3/3/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

      BEDFORD, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Monday, March 3, 2025, at 8:00 AM ET to discuss recent business progress and financial results for the fourth quarter and full year ended December 31, 2024. Conference Call and Webcast Information: Date: Monday, March 3, 2025, at 8:00 AM ET Participant Dial-In (U.S.): 1 (877) 407-9039 Participant Dial-in (International): 1 (201) 689-8470 Conference ID: 13750940 Webcast Access: Please click here The live and archived webcast can also be acce

      2/24/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUL
    Leadership Updates

    Live Leadership Updates

    See more
    • Ocular Therapeutix® to Host Investor Day on June 13, 2024

      Company to highlight corporate strategy, clinical data, and development plans for AXPAXLI™ in wet AMD and NPDR Event to feature prominent retinal disease experts Baruch D. Kuppermann, MD, PhD (University of California, Irvine) and Dilsher S. Dhoot, MD (California Retina Consultants) In-person event with virtual access to take place on June 13, 2024, at 2:00 PM ET BEDFORD, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD

      6/5/24 7:30:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ Reports First Quarter 2024 Results

      Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for AXPAXLI™ SOL-1 Phase 3 wet AMD Trial Progressing with First Subjects Randomized in April 2024 Cash Expected to Support Operations Into 2028, Based on $482.9M March 31, 2024, Cash Balance June 13, 2024, Investor Day to Outline Updated Corporate Strategy BEDFORD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degenerati

      5/7/24 4:05:00 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders

      Nadia K. Waheed, MD, MPH, Appointed Chief Medical Officer; Peter K. Kaiser, MD, to Become Chief Development Officer; Andrea Gibson, PhD, Named Vice President, Medical Collaborations; and Namrata Saroj, OD, to Become Development Strategy Consultant Dr. Waheed's strong industry track record as a CMO and broad expertise in wet AMD and diabetic retinopathy support advancing the Phase 3 AXPAXLI™ program Dr. Kaiser's vast leadership experience in numerous pivotal trials of approved wet AMD products enhances Ocular's transition to a leading retina care company Dr. Gibson and Dr. Saroj bring deep experience in clinical trial execution through their joint involvement in the development and commerc

      4/16/24 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lindstrom Richard L Md bought $69,600 worth of shares (10,000 units at $6.96), increasing direct ownership by 6% to 172,704 units (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      5/12/25 8:50:46 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summer Road Llc bought $7,000,000 worth of shares (930,851 units at $7.52) (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      2/27/24 4:43:51 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summer Road Llc bought $4,999,998 worth of shares (1,538,461 units at $3.25) (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      12/18/23 4:52:33 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care